12 Health Care Stocks Moving In Friday’s After-Market Session
Gainers Kineta (NASDAQ:KA) shares moved upwards by 28.5% to $0.67 during Friday’s after-market session. The company’s market cap…
Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday’s Mid-Day Session
Shares of AMMO, Inc. (NASDAQ:POWW) fell sharply during Friday’s session following fourth-quarter results. AMMO reported a fourth-quarter profit…
12 Health Care Stocks Moving In Thursday’s Pre-Market Session
Gainers Processa Pharma (NASDAQ:PCSA) shares moved upwards by 31.2% to $2.12 during Thursday’s pre-market session. The company’s market…
Can-Fite’s Namodenoson Featured in Biomedicines for Liver Cancer and MASH Treatment Insights
Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced
Can-Fite’s Latest Innovation: Namodenoson Shows Significant Results in Obesity Reduction
Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today reported new data on
Can-Fite Announces Exercise Of Warrants For Approximately $3M In Gross Proceeds
Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced the entry into a
Why Is Liver Cancer Focused Can-Fite BioPharma Stock Trading Higher Today?
Can-Fite BioPharma Ltd (NYSE: CANF) announced that a patient who participated in the Phase 2 Liver Cancer Study and was treated with namodenoson had a complete response and overall survival of
Matson To Rally Around 36%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page
Can-Fite Novel Approach for the Treatment of Pancreatic Carcinoma with Namodenoson Receives Appreciation of the American Association of Cancer Research (AACR)
Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncology, inflammatory and liver diseases, today announced that its study
Can-Fite’s Study On Namodenoson’s Inhibition of Pancreatic Carcinoma Receives Recognition from the American Society of Clinical Oncology (ASCO)
Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncology, inflammatory and liver diseases, today announced that its study